Neurodegeneration in multiple sclerosis: The role of oxidative stress and excitotoxicity

Journal of the Neurological Sciences

Volumn 274, Issue 1-2, 2008, Pages 48-53

  Gonsette, R E ^a  

^a National Multiple Sclerosis Center   (Belgium)

Author keywords

Excitotoxicity; Microglia; Multiple sclerosis; Oxidative stress; Peroxynitrite; Uric acid

Indexed keywords

AEOL 10150; AMPA RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; BG 0012; CALCIUM; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIMETHYLFUMARATE; FIBROBLAST GROWTH FACTOR; FP 15; FUMARIC ACID DERIVATIVE; GLUTAMIC ACID; INO 4885; INOSINE; INOSINE PHOSPHATE; ION CHANNEL; KAINIC ACID RECEPTOR ANTAGONIST; MINOCYCLINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENT; PEROXYNITRITE; PORPHYRIN DERIVATIVE; PROTEINASE; RILUZOLE; SODIUM CHANNEL BLOCKING AGENT; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; URIC ACID;

APOPTOSIS; ARTICLE; CELL INFILTRATION; CLINICAL TRIAL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; ENZYME SYNTHESIS; EXCITOTOXICITY; HUMAN; INFLAMMATION; LIPID PEROXIDATION; MICROGLIA; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NITRATION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL;

ANIMALS; EXCITATORY AMINO ACIDS; HUMANS; MULTIPLE SCLEROSIS; NERVE DEGENERATION; OXIDATIVE STRESS;

EID: 53049093018     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2008.06.029     Document Type: Article

References (96)

1. Sies H. Oxidative stress: introductory remarks. In: Sies H. (Ed). Oxidative stress (1985), Academic Press, London 1
2. Blough N.V., and Zafiriou O.C. Reaction of superoxide with nitric oxide to form peroxonitrite in alkaline aqueous solution. Inorg Chem 24 (1985) 3502-3504
3. Plumb R.C., Tantayanon R., Libby M., and Xu W.W. Chemical model for Vicking biology experiments: implication for the martian regolith. Nature 338 (1989) 633-635
4. Lymar S., and Wishart J. Reactivity of peroxynitrite: implications for handford waste management and remediation. Environmental Management Science Program Project 59982 (1998)
5. Beckman J.S., Beckman T.W., Chen J., Marshall P.A., and Freeman B.A. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 87 (1990) 1620-1624
6. Pacher P., Beckman J.S., and Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87 (2007) 315-424
7. Sayre L.M., Perry G., and Smith M.A. Oxidative stress and neurotoxicity. Chem Res Toxicol 21 (2008) 172-188
8. Van der Veen R.C., Hinton D.R., Incardonna F., and Hofman F.M. Extensive peroxynitrite activity during progressive stages of central nervous system inflammation. J Neuroimmunol 77 (1997) 1-7
9. Cross A.H., San M., Stern M.K., Keeling R.M., Salvemini D., and Misko T.P. A catalyst of peroxynitrite decomposition inhibits murine experimental autoimmune encephalomyelitis. J Neuroimmunol 107 (2000) 21-28
10. Jack C., Antel J., Brück W., and Kuhlmann T. Contrasting potential of nitric oxide and peroxynitrite to mediate oligodendrocyte injury in multiple sclerosis. Glia 55 (2007) 926-934
11. Touil T., Deloire-Grassin M.S., Vital C., Petry K.G., and Brochet B. In vivo damage of CNS myelin and axons induced by peroxynitrite. Neuroreport 12 (2001) 3637-3644
12. Szabo C., Ischiropoulos H., and Radi R. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discov 6 (2007) 662-680
13. Cross A.H., Manning P.T., Keeling R.M., Schmidt R.E., and Misko T.P. Peroxynitrite formation within the central nervous system in active multiple sclerosis. J Neuroimmunol 88 (1998) 45-56
14. Oleszak E.L., Zaczynska E., Bhattacharjee M., Butunoi C., Legido A., and Katsetos C.D. Inducible nitric oxide synthase and nitrotyrosine are found in monocytes/macrophages and/or astrocytes in acute, but not in chronic, multiple sclerosis. Clin Diagn Lab Immunol 5 (1998) 438-445
15. Liu J.S., Zhao M.L., Brosnan C.F., and Lee S.C. Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am J Pathol 158 (2001) 2057-2066
16. Hill K.E., Zollinger L.V., Watt H.E., Carlson N.G., and Rose J.W. Inducible nitric oxide synthase in chronic active multiple sclerosis plaques: distribution, cellular expression and association with myelin damage. J Neuroimmunol 151 (2004) 171-179
17. Holley J.E., Newcombe J., Winyard P.G., and Gutowski N.J. Peroxiredoxin V in multiple sclerosis lesions: predominant expression by astrocytes. Mult Scler 13 (2007) 955-961
18. Gray E., Thomas T.L., Betmouni S., Scolding N., and Love S. Elevated activity and microglial expression of myeloperoxidase in demyelinated cerebral cortex in multiple sclerosis. Brain Pathol 18 (2008) 86-95
19. Rejdak K., Eikelenboom M.J., Petzold A., Thompson E.J., Stelmasiak Z., Lazeron R.H., et al. CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis. Neurology 63 (2004) 1439-1445
20. Rejdak K., Petzold A., Stelmasiak Z., and Giovannoni G. Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis. Mult Scler 14 (2008) 59-66
21. Olney J.W. Neurotoxicity of amino acids. In: McGeer E.G., Olney J.W., and McGeer P.L. (Eds). Kainic acid as a tool in neurobiology (1978), Raven Press, New York 95-121
22. Gunasekar P.G., Kanthasamy A.G., Borowitz J.L., and Isom G.E. NMDA receptor activation produces concurrent generation of nitric oxide and reactive oxygen species: implication for cell death. J Neurochem 65 (1995) 2016-2021
23. Leist M., Fava E., Montecucco C., and Nicotera P. Peroxynitrite and nitric oxide donors induce neuronal apoptosis by eliciting autocrineexcitotoxicity. Eur J Neurosci 9 (1997) 1488-1498
24. Gonsette R.E. Oxidative stress and excitotoxicity: a therapeutic issue in multiple sclerosis?. Mult Scler 14 (2008) 22-34
25. Wallström E., Diener P., Ljungdahl A., Khademi M., Nilsson C.G., and Olsson T. Memantine abrogates neurological deficits, but not CNS inflammation, in Lewis rat experimental autoimmune encephalomyelitis. J Neurol Sci 137 (1996) 89-96
26. Pitt D., Werner P., and Raine C.S. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 6 (2000) 67-70
27. Werner P., Pitt D., and Raine C.S. Glutamate excitotoxicity-a mechanism for axonal damage and oligodendrocyte death in Multiple Sclerosis?. J Neural Transm Suppl 60 (2000) 375-385
28. Smith T., Groom A., Zhu B., and Turski L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med 6 (2000) 62-66
29. Matute C., Alberdi E., Domercq M., Perez-Cerda F., Perez-Samartin A., and Sanchez-Gomez M.V. The link between excitotoxic oligodendroglial death and demyelinating diseases. Trends Neurosci 24 (2001) 224-230
30. Follett P.L., Rosenberg P.A., Volpe J.J., and Jensen F.E. NBQX attenuates excitotoxic injury in developing white matter. J Neurosci 20 (2000) 9235-9241
31. Alberdi E., Sanchez-Gomez M.V., Torre I., Domercq M., Perez-Samartin A., Perez-Cerda F., et al. Activation of kainate receptors sensitizes oligodendrocytes to complement attack. J Neurosci 26 (2006) 3220-3228
32. Li S., and Stys P.K. Mechanisms of ionotropic glutamate receptor-mediated excitotoxicity in isolated spinal cord white matter. J Neurosci 20 (2000) 1190-1198
33. Sharp C.D., Hines I., Houghton J., Warren A., Jackson T.H., Jawahar A., et al. Glutamate causes a loss in human cerebral endothelial barrier integrity through activation of NMDA receptor. Am J Physiol Heart Circ Physiol 285 (2003) H2592-2598
34. Werner P., Pitt D., and Raine C.S. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 50 (2001) 169-180
35. Pitt D., Nagelmeier I.E., Wilson H.C., and Raine C.S. Glutamate uptake by oligodendrocytes: Implications for excitotoxicity in multiple sclerosis. Neurology 61 (2003) 1113-1120
36. Newcombe J., Uddin A., Dove R., Patel B., Turski L., Nishizawa Y., et al. Glutamate receptor expression in multiple sclerosis lesions. Brain Pathol 18 (2008) 52-61
37. Vercellino M., Merola A., Piacentino C., Votta B., Capello E., Mancardi G.L., et al. Altered glutamate reuptake in relapsing-remitting and secondary progressive multiple sclerosis cortex: correlation with microglia infiltration, demyelination, and neuronal and synaptic damage. J Neuropathol Exp Neurol 66 (2007) 732-739
38. Tilleux S., and Hermans E. Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. J Neurosci Res 85 (2007) 2059-2070
39. Dal Bianco A., Bradl M., Frischer J., Kutzelnigg A., Jellinger K., and Lassmann H. Multiple sclerosis and Alzheimer's disease. Ann Neurol 63 (2008) 174-178
40. Zhang Y.J., Xu Y.F., Liu Y.H., Yin J., Li H.L., Wang Q., et al. Peroxynitrite induces Alzheimer-like tau modifications and accumulation in rat brain and its underlying mechanisms. FASEB J 20 (2006) 1431-1442
41. Skaper S.D. The brain as a target for inflammatory processes and neuroprotective strategies. Ann N Y Acad Sci 1122 (2007) 23-34
42. Van der Veen R.C., and Roberts L.J. Contrasting roles for nitric oxide and peroxynitrite in the peroxidation of myelin lipids. J Neuroimmunol 95 (1999) 1-7
43. Orrell R.W. AEOL-10150 (Aeolus). Curr Opin Investig Drugs 7 (2006) 70-80
44. Benatar M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis 26 (2007) 1-13
45. Nguyen T., Sherratt P.J., and Pickett C.B. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu Rev Pharmacol Toxicol 43 (2003) 233-260
46. Chen X.L., Dodd G., Thomas S., Zhang X., Wasserman M.A., Rovin B.H., et al. Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression. Am J Physiol Heart Circ Physiol 290 (2006) H1862-1870
47. Schreibelt G., Van Horssen J., Van Rossum S., Dijkstra C.D., Drukarch B., and De Vries H.E. Therapeutic potential and biological role of endogenous antioxidant enzymes in multiple sclerosis pathology. Brain Res Rev 56 (2007) 322-330
48. Burdo J., Schubert D., and Maher P. Glutathione production is regulated via distinct pathways in stressed and non-stressed cortical neurons. Brain Res 1189 (2008) 12-22
49. Liu Y., Zhu B., Luo L., Li P., Paty D.W., and Cynader M.S. Heme oxygenase-1 plays an important protective role in experimental autoimmune encephalomyelitis. Neuroreport 12 (2001) 1841-1845
50. Guy J., Qi X., Wang H., and Hauswirth W.W. Adenoviral gene therapy with catalase suppresses experimental optic neuritis. Arch Ophthalmol 117 (1999) 1533-1539
51. Wierinckx A., Brevé J., Mercier D., Schultzberg M., Drukarch B., and Van Dam A.M. Detoxication enzyme inducers modify cytokine production in rat mixed glial cells. J Neuroimmunol 166 (2005) 132-143
52. Vargas M.R., Pehar M., Cassina P., Beckman J.S., and Barbeito L. Increased glutathione biosynthesis by Nrf2 activation in astrocytes prevents p75NTR-dependent motor neuron apoptosis. J Neurochem 97 (2006) 687-696
53. Schimrigk S., Brune N., Hellwig K., Lukas C., Bellenberg B., Rieks M., et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol 13 (2006) 604-610
54. Gold R., Fox R., Dawson K., O'Neill G., Yang M., and Panzara M. Two phase 3 studies to determine the efficacy and safety of BG00012, a novel oral fumaric acid derivative, in patients with relapsing remitting multiple sclerosis. Mult Scler 13 (2007) S173 P579
55. Ames B.N., Cathcart R., Schwiers E., and Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 78 (1981) 6858-6862
56. Squadrito G.L., Cueto R., Splenser A.E., Valavanidis A., Zhang H., Uppu R.M., et al. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys 376 (2000) 333-337
57. Stinefelt B., Leonard S.S., Blemings K.P., Shi X., and Klandorf H. Free radical scavenging, DNA protection, and inhibition of lipid peroxidation mediated by uric acid. Ann Clin Lab Sci 35 (2005) 37-45
58. Spitsin S.V., Scott G.S., Mikheeva T., Zborek A., Kean R.B., Brimer C.M., et al. Comparison of uric acid and ascorbic acid in protection against EAE. Free Radic Biol Med 33 (2002) 1363-1371
59. Hooper D.C., Scott G.S., Zborek A., Mikheeva T., Kean R.B., Koprowski H., et al. Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis. FASEB J 14 (2000) 691-698
60. Scott G.S., Bowman S.R., Smith T., Flower R.J., and Bolton C. Glutamate-stimulated peroxynitrite production in a brain-derived endothelial cell line is dependent on N-methyl-D-aspartate (NMDA) receptor activation. Biochem Pharmacol 73 (2007) 228-236
61. Du Y., Chen C.P., Tseng C.Y., Eisenberg Y., and Firestein B.L. Astroglia-mediated effects of uric acid to protect spinal cord neurons from glutamate toxicity. Glia 55 (2007) 463-472
62. Glantz L., Avramovich A., Trembovler V., Gurvitz V., Kohen R., Eidelman L.A., et al. Ischemic preconditioning increases antioxidants in the brain and peripheral organs after cerebral ischemia. Exp Neurol 192 (2005) 117-124
63. Kean R.B., Spitsin S.V., Mikheeva T., Scott G.S., and Hooper D.C. The peroxynitrite scavenger uric acid prevents inflammatory cell invasion into the central nervous system in experimental allergic encephalomyelitis through maintenance of blood-central nervous system barrier integrity. J Immunol 165 (2000) 6511-6518
64. Scott G.S., Cuzzocrea S., Genovese T., Koprowski H., and Hooper D.C. Uric acid protects against secondary damage after spinal cord injury. Proc Natl Acad Sci U S A 102 (2005) 3483-3488
65. Liu F., You S.W., Yao L.P., Liu H.L., Jiao X.Y., Shi M., et al. Secondary degeneration reduced by inosine after spinal cord injury in rats. Spinal Cord 44 (2006) 421-426
66. Yu Z.F., Bruce-Keller A.J., Goodman Y., and Mattson M.P. Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J Neurosci Res 53 (1998) 613-625
67. Chamorro A., Planas A.M., Muner D.S., and Deulofeu R. Uric acid administration for neuroprotection in patients with acute brain ischemia. Med Hypotheses 62 (2004) 173-176
68. Kutzing M.K., and Firestein B.L. Altered uric acid levels and disease states. J Pharmacol Exp Ther 324 (2008) 1-7
69. Hooper D.C., Spitsin S., Kean R.B., Champion J.M., Dickson G.M., Chaudhry I., et al. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A 95 (1998) 675-680
70. Spitsin S., Hooper D.C., Mikheeva T., and Koprowski H. Uric acid levels in patients with multiple sclerosis: analysis in mono- and dizygotic twins. Mult Scler 7 (2001) 165-166
71. Knapp C.M., Constantinescu C.S., Tan J.H., McLean R., Cherryman G.R., and Gottlob I. Serum uric acid levels in optic neuritis. Mult Scler 10 (2004) 278-280
72. Peng F., Zhang B., Zhong X., Li J., Xu G., Hu X., et al. Serum uric acid levels of patients with multiple sclerosis and other neurological diseases. Mult Scler 14 (2008) 188-196
73. Annanmaki T., Muuronen A., and Murros K. Low plasma uric acid level in Parkinson's disease. Mov Disord 22 (2007) 1133-1137
74. Kim T.S., Pae C.U., Yoon S.J., Jang W.Y., Lee N.J., Kim J.J., et al. Decreased plasma antioxidants in patients with Alzheimer's disease. Int J Geriatr Psychiatry 21 (2006) 344-348
75. de Lau L.M., Koudstaal P.J., Hofman A., and Breteler M.M. Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 58 (2005) 797-800
76. Weisskopf M.G., O'Reilly E., Chen H., Schwarzschild M.A., and Ascherio A. Plasma urate and risk of Parkinson's disease. Am J Epidemiol 166 (2007) 561-567
77. Alonso A., Rodriguez L.A., Logroscino G., and Hernan M.A. Gout and risk of Parkinson disease: a prospective study. Neurology 69 (2007) 1696-1700
78. Drulovic J., Dujmovic I., Stojsavljevic N., Mesaros S., Andjelkovic S., Miljkovic D., et al. Uric acid levels in sera from patients with multiple sclerosis. J Neurol 248 (2001) 121-126
79. Toncev G., Milicic B., Toncev S., and Samardzic G. Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol 9 (2002) 221-226
80. Sotgiu S., Pugliatti M., Sanna A., Sotgiu A., Fois M.L., Arru G., et al. Serum uric acid and multiple sclerosis. Neurol Sci 23 (2002) 183-188
81. Deretzi G., Pelidou S.H., Zacharakis G., and Kyritsis A.P. Serum levels of uric acid in patients with multiple sclerosis: a biological marker in clinical course and treatment of MS. Mult Scler 9 (2003) S100 P412
82. Rentzos M., Nikolaou C., Anagnostouli M., Rombos A., Tsakanikas K., Economou M., et al. Serum uric acid and multiple sclerosis. Clin Neurol Neurosurg 108 (2006) 527-531
83. Toncev G., Milicic B., Toncev S., and Samardzic G. High-dose methylprednisolone therapy in multiple sclerosis increases serum uric acid levels. Clin Chem Lab Med 40 (2002) 505-508
84. Constantinescu C.S., Freitag P., and Kappos L. Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis. Mult Scler 6 (2000) 378-381
85. Toncev G., Miletic Drakulic S., and Knezevic Z. Higher serum uric acid levels after treatment with interferon beta-1b. Mult Scler 12 (2006) S81 P312
86. Spitsin S., Hooper D.C., Leist T., Streletz L.J., Mikheeva T., and Koprowski H. Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease. Mult Scler 7 (2001) 313-319
87. Toncev G., Milicic B., Perovic S., Toncev F., Ziatic G., and Knezevic Z. Inosine in the treatment of multiple sclerosis: an open-label study in 32 patients. Neurology 64 suppl1 (2005) A383 poster 06.151
88. Hooper DC. Treatment of multiple sclerosis using over the counter inosine. Clinical-trial gov 2003; NCT 000 67327.
89. Gonsette R.E. Association of beta interferon and inosine in relapsing-remitting multiple sclerosis. Mult scler 9 (2003) S141 P563
90. Marik C., Felts P.A., Bauer J., Lassmann H., and Smith K.J. Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity?. Brain 130 (2007) 2800-2815
91. Coles A.J., Cox A., Le Page E., Jones J., Trip S.A., Deans J., et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 253 (2006) 98-108
92. Coles A.J., and and the CAMMS223 study group. Alemtuzumab improved multiple sclerosis functional composite scores and delayed time to first relapse at 2-year interim analysis compared to subcutaneous interferon beta-1a. Mult Scler 13 (2007) S166 poster P557
93. Killestein J., Kalkers N.F., and Polman C.H. Glutamate inhibition in MS: the neuroprotective properties of riluzole. J Neurol Sci 233 (2005) 113-115
94. Gordon P.H., Moore D.H., Miller R.G., Florence J.M., Verheijde J.L., Doorish C., et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 6 (2007) 1045-1053
95. Muzio L., Martino G., and Furlan R. Multifaceted aspects of inflammation in multiple sclerosis: the role of microglia. J Neuroimmunol 191 (2007) 39-44
96. Black J.A., Liu S., Carrithers M., Carrithers L.M., and Waxman S.G. Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine. Ann Neurol 62 (2007) 21-33